Cartesian Therapeutics (RNAC) Other Non-Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Other Non-Current Liabilities data on file, last reported at $47000.0 in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $47000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $47000.0 (changed N/A YoY), and the FY2025 annual result was $141000.0, down 96.32% from the prior year.
• Other Non-Current Liabilities declined to $47000.0 in Q1 2026 per RNAC's latest filing, from $141000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $33.5 million in Q3 2022 and troughed at $47000.0 in Q1 2026.
• A 5-year average of $12.6 million and a median of $10.0 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities jumped 236.12% in 2023, then sank 96.32% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $19.1 million in 2022, then slumped by 66.59% to $6.4 million in 2023, then plunged by 40.01% to $3.8 million in 2024, then slumped by 96.32% to $141000.0 in 2025, then sank by 66.67% to $47000.0 in 2026.
• Business Quant data shows RNAC's Other Non-Current Liabilities at $47000.0 in Q1 2026, $141000.0 in Q4 2025, and $848000.0 in Q3 2025.